Content type

Multinational Drugmakers Will Increase Partnerships With Domestic Firms To Deepen Market Penetration In Mainland China

Pharmaceuticals / China / Wed 31 Jan, 2024

Key View

  • Foreign pharmaceutical companies will continue to cast a vote of confidence in Mainland China's medicine market and will expand investment.
  • We believe in 2024 multinational companies will increasingly partner with local companies in Mainland China to leverage the synergies of both foreign and domestic companies.
  • Mainland China's
Read More

Quick View: Envision Energy’s Collaboration With International Drugmakers In Mainland China Will Advance Sustainability In The Sector

Pharmaceuticals / China / Mon 22 Jan, 2024

The Latest: On January 18 2024, AstraZeneca, Lonza, Novartis, Novo Nordisk and Roche signed a three-year deal to purchase renewable energy from Envision Energy, a multination corporation based in Mainland China, to power their manufacturing facilities in the country. The aim is to stem worsening emissions in the global healthcare industry. From

Read More

Mainland China’s Crude Oil Imports Set To Surge In 2024

Oil & Gas / China / Tue 09 Jan, 2024

Key View

  • Mainland China’s crude oil imports in 2024 are set to rise as the government raised import quotas for private refiners.
  • Refining capacity additions are set to support crude oil imports in the short and medium terms.
  • Resurgent fuel demand is expected to maintain higher utilization rates, generating upward pressure on crude oil
Read More

Quick View: AstraZeneca’s Acquisition Of Mainland China’s Biotech Firm Will Enrich Drugmakers Pipeline In Cell Therapies

Pharmaceuticals / China / Tue 02 Jan, 2024

The Latest: On December 26 2023, AstraZeneca announced its plan to make one of its first acquisitions in Mainland China and acquire Gracell Biotechnologies for up to USD1.2bn to increase its investment in cell therapies for treating cancer. The proposed acquisition will add a potential new treatment for multiple myeloma, a type of bone marrow

Read More

Mainland China Growth Update: 2024 Outlook Growing More Uncertain

Country Risk / China / Mon 18 Dec, 2023

Key View

  • High frequency indicators suggest year-on-year GDP growth accelerated in the October-November period.
  • However, that is largely due to a more favourable base of comparison in the same period in 2022, which suffered widespread Covid disruptions.
  • We have revised our 2023 GDP growth forecast upward to 5.5%, from 5.2%, but retain our
Read More

Mainland China Signals 5% Growth Target For 2024

Country Risk / China / Wed 13 Dec, 2023

Key View

  • Beijing stressed the importance of making “economic progress” at its annual Central Economic Work Conference on December 12.
  • We take this to mean that it will set a growth target of around 5% at the upcoming Two Meetings (lianghui) in March.
  • However, a weak global economic outlook in 2024 and the ongoing housing market downturn
Read More
Download Indicator Summary
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Clearbit Form
 

Thank you. Your download link will be emailed to you shortly.